Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxazosin XL for Stress-Induced Alcohol Relapse Risk
NCT03398252Phase 1Withdrawn
- Sponsor
- UTHealth Houston
- Start
- May 2022
- Primary completion
- Oct 2023
01
Overview
Phase 1, randomised, double-blind trial of doxazosin in alcohol use disorder (AUD), sponsored by UTHealth Houston. Primary endpoint: Feasibility as study attendance at 2 weeks. Planned start May 2022; status: withdrawn.
02
Drugs
doxazosin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03398252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398252.